Eagle Pharmaceuticals Inc (EGRX) : Park West Asset Management scooped up 782,197 additional shares in Eagle Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,472,197 shares of Eagle Pharmaceuticals Inc which is valued at $91,349,824.Eagle Pharmaceuticals Inc makes up approximately 8.17% of Park West Asset Management’s portfolio.
Other Hedge Funds, Including , Jane Street Group added EGRX to its portfolio by purchasing 5,112 company shares during the most recent quarter which is valued at $317,200.Acrospire Investment Management reduced its stake in EGRX by selling 300 shares or 30.0% in the most recent quarter. The Hedge Fund company now holds 700 shares of EGRX which is valued at $33,852. Eagle Pharmaceuticals Inc makes up approx 0.02% of Acrospire Investment Management’s portfolio.
Eagle Pharmaceuticals Inc closed down -0.73 points or -1.22% at $59.02 with 13,54,763 shares getting traded on Thursday. Post opening the session at $59.99, the shares hit an intraday low of $57.48 and an intraday high of $59.99 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Eagle Pharmaceuticals Inc reported $0.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $0.71. The company had revenue of $40.90 million for the quarter, compared to analysts expectations of $39.20 million. The company’s revenue was up 581.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.53 EPS.
Many Wall Street Analysts have commented on Eagle Pharmaceuticals Inc. Company shares were Reiterated by Mizuho on Aug 16, 2016 to “Neutral”, Firm has raised the Price Target to $ 65 from a previous price target of $47 .Shares were Downgraded by Mizuho on Jun 20, 2016 to ” Neutral” and Lowered the Price Target to $ 47 from a previous price target of $66 .
Eagle Pharmaceuticals Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD) an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda and Ryanodex (dantrolene for MH) and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101 EP-3102 Ryanodex EP-4104 EP-6101 EP-5101 EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.